Cancer Focused Clovis Oncology Files For Bankruptcy
- ByBenzinga-
Benzinga - Clovis Oncology Inc (NASDAQ: CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a...
Symbol | Exchange | Currency |
|---|
Benzinga - Clovis Oncology Inc (NASDAQ: CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a...
Investing.com - Clovis reported on Friday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Clovis announced earnings per share of...
A lot happened in the markets this past week. And perhaps the best analogy to explain it all rests with one obscure development in the broader world of economics: The price of eggs...
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Neutral | Neutral | Strong Sell | Neutral | Strong Sell |
| Summary | Sell | Sell | Strong Sell | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 91.00 | 93.80 | 91.00 | -3.80 | -4.01% | 70.94K | London | |||
| 1.40 | 1.40 | 1.055 | 0.00 | 0.00% | 0.00 | London | |||
| 3.19 | 3.19 | 3.19 | 0.00 | 0.00% | 0.00 | London | |||
| 7.10 | 7.10 | 6.00 | 0.00 | 0.00% | 0.00 | London | |||
| 6.25 | 6.30 | 6.16 | +0.200 | +3.31% | 8.36M | London | |||
| 9.95 | 9.50 | 9.50 | -0.45 | -4.52% | 20.69K | London | |||
| 34.65 | 35.20 | 35.00 | +0.65 | +1.88% | 369.95K | London | |||
| 1.06 | 1.06 | 1.06 | 0.00 | 0.00% | 0.00 | London | |||
| 11.50 | 11.50 | 11.50 | 0.00 | 0.00% | 0.00 | London | |||
| 1,812.50 | 1,812.50 | 1,812.50 | 0.00 | 0.00% | 0.00 | London | |||
| 669.00 | 670.00 | 669.00 | 0.00 | 0.00% | 0.00 | London | |||
| 1.25 | 1.002 | 1.002 | 0.00 | 0.00% | 0.00 | London | |||
| 4.96 | 5.06 | 4.83 | 0.00 | 0.00% | 0.00 | London | |||
Catlinderived | 708.50 | 708.50 | 708.50 | 0.00 | 0.00% | 0.00 | London | ||
| 46.50 | 46.50 | 46.50 | 0.00 | 0.00% | 20.01K | London |